Not a good buy right now for an impatient investor: price trend is bearish and momentum is weakening.
No Intellectia proprietary buy signals today (no AI Stock Picker, no SwingMax), so there’s no “must-buy-now” trigger.
Options positioning is skewed bearish/defensive (high put open interest vs calls) while actual option trading activity is extremely thin.
With no fresh news catalysts and fundamentals still in cash-burn mode, the risk/reward favors avoiding new entries until the stock reclaims key resistance levels.
Technical Analysis
Trend: Bearish (SMA_200 > SMA_20 > SMA_5), confirming a sustained downtrend across short/medium/long timeframes.
Momentum: MACD histogram -0.00505 and negatively expanding → downside momentum is strengthening.
RSI(6): 39.842 (neutral-to-weak) → not oversold enough to signal a high-conviction dip-buy.
Levels: Pivot 8.045 is overhead; resistance at 8.553 (R1) then 8.867 (R2). Support at 7.537 (S1) then 7.223 (S2).
Near-term pattern stats: 60% chance of ~-0.88% next day; modestly positive bias over 1 week (+2.12%) and 1 month (+3.34%), but this is counter-trend and less reliable without a reversal signal.
Market context: S&P 500 -0.26% (slightly risk-off), not supportive for speculative biotech names.
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/Sentiment: Put OI 4542 vs Call OI 1190 → Open Interest Put/Call 3.82, a bearish/defensive skew.
Activity: Today’s option volume is only 2 contracts (puts traded: 0), so the put/call volume ratio of 0.0 is not informative due to near-zero liquidity.
Volatility: 30D IV ~286.33% vs historical vol ~43.91% → extremely elevated implied volatility, consistent with high event/risk premium typical of small biotech.
IV percentile ~45.5 / IV rank ~49.71 → elevated but not at extremes versus its own history.
Takeaway: Skew suggests caution, but the lack of real trading volume reduces confidence in the options signal quality.
Net income: -10.083M, down -46.48% YoY (loss widened).
EPS: -0.60, down -56.83% YoY (deteriorating per-share profitability).
Gross margin: 0 (consistent with no revenue).
Overall: fundamentals indicate ongoing cash burn with worsening losses, which typically pressures the stock absent strong clinical/business catalysts.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target trend data provided, implying limited coverage or no recent updates.
Wall Street “pros” view (inferred from typical coverage dynamics for pre-revenue biotech): upside depends on pipeline/clinical milestones rather than current financials.
Wall Street “cons” view: widening losses, no revenue base, and high volatility make timing and drawdowns difficult—especially without a fresh catalyst.
Politicians/congress/influential trading: No recent congress trading data available; no politician activity provided.
Wall Street analysts forecast ELTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELTX is 15.5 USD with a low forecast of 13 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ELTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELTX is 15.5 USD with a low forecast of 13 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.610
Low
13
Averages
15.5
High
18
Current: 7.610
Low
13
Averages
15.5
High
18
H.C. Wainwright
Buy
maintain
$10 -> $13
AI Analysis
2025-07-17
Reason
H.C. Wainwright
Price Target
$10 -> $13
AI Analysis
2025-07-17
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Elicio Therapeutics to $13 from $10 and keeps a Buy rating on the shares. The firm says investor focus is on the interim analysis from the randomized Phase 2 portion of the AMPLIFY-7P trial in Q3.
